Men whose prostate cancer comes back after surgery and get radiation therapy when their PSA is still very low (under 50 ng/L) live longer and are less likely to get cancer spread than those who wait until their PSA is much higher.
Scientific Claim
Starting salvage radiotherapy (SRT) at an ultrasensitive PSA level below 50 ng/L is associated with significantly better 5-year overall survival and reduced risk of metastasis compared to starting SRT at PSA levels above 500 ng/L in men with prostate cancer recurrence after radical prostatectomy.
Original Statement
“Patients with a PSA ≤ 0.5 µg/L (≤500 ng/L) at the start of SRT lived longer free of new metastases than patients with a PSA > 0.5 µg/L (>500 ng/L). ... SRT given at extremely low PSA values combined the advantages of ART and SRT and avoided the cons.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim uses 'associated with' and reflects the observational nature of the included studies. It does not claim causation, which is appropriate given the absence of RCTs.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether initiating SRT at PSA <50 ng/L directly improves survival compared to SRT at PSA >200 ng/L.
Whether initiating SRT at PSA <50 ng/L directly improves survival compared to SRT at PSA >200 ng/L.
What This Would Prove
Whether initiating SRT at PSA <50 ng/L directly improves survival compared to SRT at PSA >200 ng/L.
Ideal Study Design
A multicenter, double-blind RCT of 1,200 men with PSA recurrence after radical prostatectomy and undetectable imaging, randomized to immediate SRT (PSA 20–50 ng/L) vs. delayed SRT (PSA 200–500 ng/L), with primary endpoint of 7-year metastasis-free survival and secondary endpoints of overall survival and urinary toxicity, using standardized ultrasensitive PSA assays.
Limitation: Cannot determine if the benefit is due to earlier treatment or lower tumor burden at treatment initiation.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThe pooled effect size of SRT initiation timing on survival across all available observational data.
The pooled effect size of SRT initiation timing on survival across all available observational data.
What This Would Prove
The pooled effect size of SRT initiation timing on survival across all available observational data.
Ideal Study Design
A meta-analysis of individual patient data from 15+ prospective cohorts (n≥30,000) comparing SRT initiation at PSA <50 ng/L vs. 50–200 ng/L vs. >200 ng/L, adjusting for PSA doubling time, Gleason score, and surgical margins, with standardized outcome definitions.
Limitation: Cannot eliminate selection bias—men with lower PSA may have less aggressive disease.
Prospective Cohort StudyLevel 2aIn EvidenceThe natural history of PSA kinetics and survival outcomes based on SRT timing in a real-world population.
The natural history of PSA kinetics and survival outcomes based on SRT timing in a real-world population.
What This Would Prove
The natural history of PSA kinetics and survival outcomes based on SRT timing in a real-world population.
Ideal Study Design
A prospective cohort of 3,000 men with PSA recurrence after prostatectomy, tracked with monthly ultrasensitive PSA and annual PSMA PET/CT, with SRT initiated at predefined PSA thresholds (20, 100, 200, 500 ng/L), recording metastasis and death over 10 years.
Limitation: Cannot prove causation due to non-randomized treatment assignment.
Evidence from Studies
Supporting (1)
The study found that starting treatment when PSA is very, very low leads to better survival, which matches the idea that starting treatment earlier (at lower PSA) is better — even if it didn’t test exactly 50 vs. 500.